| Added by | mollevi |
|---|---|
| Last modified by | standudu |
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer |
| Creator | Himoto et al. |
| Author | Yuki Himoto |
| Author | Harini Veeraraghavan |
| Author | Junting Zheng |
| Author | Dmitriy Zamarin |
| Author | Alexandra Snyder |
| Author | Marinela Capanu |
| Author | Stephanie Nougaret |
| Author | Hebert A. Vargas |
| Author | Fuki Shitano |
| Author | Margaret Callahan |
| Author | Wei Wang |
| Author | Evis Sala |
| Author | Yulia Lakhman |
| Abstract | PURPOSE: To determine if radiomic measures of tumor heterogeneity derived from baseline contrast-enhanced computed tomography (CE-CT) are associated with durable clinical benefit and time to off-treatment in patients with recurrent ovarian cancer (OC) enrolled in prospective immunotherapeutic trials. MATERIALS AND METHODS: This retrospective study included 75 patients with recurrent OC who were enrolled in prospective immunotherapeutic trials (n = 74) or treated off-label (n = 1) and had baseline CE-CT scans. Disease burden (total tumor volume, number of disease sites), radiomic measures of intertumor heterogeneity (cluster-site entropy, cluster-site dissimilarity), and intratumor heterogeneity of the largest lesion (Haralick texture features) were computed. Associations of clinical, conventional imaging, and radiomic measures with durable clinical benefit and time to off-treatment were examined. RESULTS: In univariable analysis, fewer disease sites, lower intertumor heterogeneity (lower cluster-site entropy, lower cluster-site dissimilarity), and lower intratumor heterogeneity of the largest lesion (higher energy) were significantly associated with durable clinical benefit (P ? .031). More disease sites, presence of pleural disease and/or distant metastases, higher intertumor heterogeneity (higher cluster-site entropy, higher cluster-site dissimilarity), and higher intratumor heterogeneity of the largest lesion (higher Contrastlargest-lesion) were significantly associated with shorter time to off-treatment (P ? .034). In multivariable analysis, higher Energylargest-lesion (indicator of lower intratumor heterogeneity; P = .006; odds ratio, 1.41) and fewer disease sites (P = .003; odds ratio, 1.64) remained significant indicators of durable clinical benefit (multivariable model C-index, 0.821). Higher cluster-site dissimilarity (indicator of higher intertumor heterogeneity) was a modest but single independent indicator of shorter time to off-treatment (P = .004; hazard ratio, 1.19; C-index, 0.6). CONCLUSION: Fewer disease sites and lower intra- and intertumor heterogeneity modeled from the baseline CE-CT may indicate better response of OC to immunotherapy. |
| Publication | JCO precision oncology |
| Volume | 3 |
| Date | 2019 |
| Journal Abbr | JCO Precis Oncol |
| Language | eng |
| DOI | 10.1200/PO.19.00038 |
| ISSN | 2473-4284 |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 32914033 PMCID: PMC7446503 |
| Date Added | 2020/09/23 - 15:59:18 |
| Date Modified | 2020/12/02 - 20:20:31 |
| Notes and Attachments | PubMed entry (Attachment) Version acceptée (Attachment) |
Institut de Recherche en Cancérologie de
